This study will evaluate the safety, tolerability and efficacy of a single dose level of KB003 in subjects with inadequately controlled asthma.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
160
Anti-GM-CSF Monoclonal Antibody 400mg
Normal Saline
Change in Percent Predicted FEV1 at Week 24
Time frame: Baseline to Week 24
To Evaluate the Efficacy of KB003 as Measured by Asthma Exacerbation Rate
Time frame: Week 24
To Evaluate the Effect of KB003 on Peak Expiratory Flow (PEF)
Time frame: Week 24
To Evaluate the Safety and Tolerability of KB003 as Measured by Frequency and Severity of AEs, Clinical Safety, Laboratory Abnormalities and Chest Radiographic Assessments
Time frame: Week 24
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Birmingham, Alabama, United States
Unnamed facility
Fullerton, California, United States
Unnamed facility
Granada Hills, California, United States
Unnamed facility
Los Angeles, California, United States
Unnamed facility
Rancho Mirage, California, United States
Unnamed facility
Sacramento, California, United States
Unnamed facility
San Jose, California, United States
Unnamed facility
Centennial, Colorado, United States
Unnamed facility
Colorado Springs, Colorado, United States
Unnamed facility
Denver, Colorado, United States
...and 60 more locations